- Home
- COP vs GSK Comparison
COP vs GSK Comparison
Compare COP & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COP | GSK |
|---|---|---|
| Founded | 1917 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5B | 96.1B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | COP | GSK |
|---|---|---|
| Price | $114.75 | $55.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 2 |
| Target Price | ★ $114.65 | N/A |
| AVG Volume (30 Days) | ★ 8.0M | 5.3M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | 2.87% | ★ 3.22% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.35 | N/A |
| Revenue | ★ $58,944,000,000.00 | N/A |
| Revenue This Year | N/A | $6.81 |
| Revenue Next Year | $6.46 | $4.74 |
| P/E Ratio | ★ $18.42 | $32.75 |
| Revenue Growth | ★ 7.67 | N/A |
| 52 Week Low | $79.88 | $32.38 |
| 52 Week High | $122.50 | $61.70 |
Technical Indicators
Market Signals| Indicator | COP | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 45.52 |
| Support Level | $91.18 | $47.89 |
| Resistance Level | $122.50 | $60.37 |
| Average True Range (ATR) | 2.97 | 0.90 |
| MACD | -0.14 | -0.81 |
| Stochastic Oscillator | 45.17 | 20.16 |
Price Performance
Historical ComparisonAbout COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.